KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Zimmer Biomet Holdings (ZBH) Cost of Revenue (2016 - 2025)

Zimmer Biomet Holdings has reported Cost of Revenue over the past 17 years, most recently at $792.4 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $792.4 million for Q4 2025, up 35.06% from a year ago — trailing twelve months through Dec 2025 was $2.5 billion (up 13.81% YoY), and the annual figure for FY2025 was $2.5 billion, up 13.81%.
  • Cost of Revenue for Q4 2025 was $792.4 million at Zimmer Biomet Holdings, up from $559.3 million in the prior quarter.
  • Over the last five years, Cost of Revenue for ZBH hit a ceiling of $792.4 million in Q4 2025 and a floor of $436.3 million in Q1 2021.
  • Median Cost of Revenue over the past 5 years was $522.9 million (2022), compared with a mean of $537.4 million.
  • Peak annual rise in Cost of Revenue hit 56.28% in 2021, while the deepest fall reached 13.7% in 2021.
  • Zimmer Biomet Holdings' Cost of Revenue stood at $536.5 million in 2021, then decreased by 3.02% to $520.3 million in 2022, then increased by 3.56% to $538.8 million in 2023, then increased by 8.89% to $586.7 million in 2024, then skyrocketed by 35.06% to $792.4 million in 2025.
  • The last three reported values for Cost of Revenue were $792.4 million (Q4 2025), $559.3 million (Q3 2025), and $592.2 million (Q2 2025) per Business Quant data.